![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Janssen Gains FDA Approval for Type 2 Diabetes Combo Drug Invokamet XR
Janssen Gains FDA Approval for Type 2 Diabetes Combo Drug Invokamet XR
September 29, 2016
The FDA approved Janssen’s Invokamet XR, a once-daily combination of canagliflozin and metformin hydrochloride, for use with diet and exercise to improve blood glucose control in adults with type 2 diabetes.
Invokamet XR combines Invokana (canagliflozin) and an extended release formulation of metformin.
Upcoming Events
-
21Oct